Short answer
Bio-Techne (TECH) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $311M (down 1.5% year over year) with net income of $51M.
Q1 2026 key financials · XBRL
- Revenue
- $311M
- −1.5% YoY · +5.3% QoQ
- Net income
- $51M
- +126.0% YoY · +34.3% QoQ
- Operating margin
- 24.2%
- Gross margin
- 66.9%
- EPS (diluted)
- $0.32
- +113.3% YoY · +28.0% QoQ
Source: XBRL data from the Bio-Techne (TECH) Q1 2026 10-Q on SEC EDGAR. USD.
Bio-Techne Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $311.4M, down 2% YoY from $316.2M
- Gross margin 66.9% vs 67.9% YoY; adjusted gross margin 70.4% vs 71.6%
- Diagnostics and Spatial Biology revenue $85.6M, down 4%; operating margin 12.1% vs 9.4%
- Protein Sciences revenue $226.2M, down 1%; operating margin 44.2% vs 45.6%
- Cash and investments $214.1M vs $162.2M; nine-month operating cash flow $196.7M vs $189.4M
- Fiscal 2026 capital expenditures approximately $7M remaining; gross margins subject to portfolio mix and headwinds include supply-chain challenges, competition, and currency fluctuations
Risk Factors
- No material risk-factor changes during quarter or nine months ended March 31, 2026
- Carried-forward risks remain those disclosed in the June 30, 2025 Form 10-K
- No newly triggered regulatory, legal, compliance, operational, competitive, market, or financial risks identified in this filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bio-Techne quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.